[HTML][HTML] Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with …
J Baselga, P Gómez, R Greil, S Braga… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal
Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative …
Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative …
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised …
M Colleoni, W Luo, P Karlsson, J Chirgwin… - The lancet …, 2018 - thelancet.com
Background In animal models of breast cancer, resistance to continuous use of letrozole can
be reversed by withdrawal and reintroduction of letrozole. We therefore hypothesised that …
be reversed by withdrawal and reintroduction of letrozole. We therefore hypothesised that …
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
J De Grève, T Moran, MP Graas, D Galdermans… - Lung Cancer, 2015 - Elsevier
Objectives Afatinib, an oral irreversible ErbB family blocker, has demonstrated efficacy in
patients with epidermal growth factor receptor (EGFR) mutation-positive advanced lung …
patients with epidermal growth factor receptor (EGFR) mutation-positive advanced lung …
Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial
D Tripathy, SM Tolaney, AD Seidman… - JAMA …, 2022 - jamanetwork.com
Importance Patients with breast cancer and brain metastases (BM) have a poor prognosis
and high clinical need for novel treatments; however, historically, studies have often …
and high clinical need for novel treatments; however, historically, studies have often …
[HTML][HTML] Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and …
Background Late recurrences in postmenopausal women with hormone receptor-positive
breast cancers remain an important challenge. Avoidance or delayed development of …
breast cancers remain an important challenge. Avoidance or delayed development of …
[HTML][HTML] The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
A Wardley, J Cortes, L Provencher, K Miller… - Breast cancer research …, 2021 - Springer
Purpose Androgen receptor (AR) expression occurs in up to 86% of human epidermal
growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance …
growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance …
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer
Purpose: Abiraterone may suppress androgens that stimulate breast cancer growth. We
conducted a biomarker analysis of circulating tumor cells (CTCs), formalin-fixed paraffin …
conducted a biomarker analysis of circulating tumor cells (CTCs), formalin-fixed paraffin …
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–Positive Early Breast Cancer: Results from the SOLE Trial
E Guerini-Rocco, KP Gray, C Fumagalli… - Clinical Cancer …, 2021 - AACR
Purpose: Women with hormone receptor–positive early breast cancers have a persistent risk
of relapse and biomarkers for late recurrence are needed. We sought to identify tumor …
of relapse and biomarkers for late recurrence are needed. We sought to identify tumor …
Dietetic and psychological mindfulness workshops for the management of cachectic cancer patients. A randomized study
C Focan, G Houbiers, L Gilles… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: To determine if actively-treated cancer patients developing cachexia could benefit from
participation to mindfulness workshops. Patients and Methods: Subjects developing …
participation to mindfulness workshops. Patients and Methods: Subjects developing …
Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the …
I Vergote, E Van Nieuwenhuysen… - International Journal of …, 2022 - ijgc.bmj.com
Objective Because elderly patients with ovarian cancer are underrepresented in randomized
studies, this study aimed to expand our knowledge on the safety and effectiveness of …
studies, this study aimed to expand our knowledge on the safety and effectiveness of …